The stock of PTC Therapeutics Inc (PTCT) has seen a -12.98% decrease in the past week, with a -7.38% drop in the past month, and a 8.26% flourish in the past quarter. The volatility ratio for the week is 5.58%, and the volatility levels for the past 30 days are at 4.69% for PTCT. The simple moving average for the last 20 days is -9.69% for PTCT stock, with a simple moving average of 17.86% for the last 200 days.
Is It Worth Investing in PTC Therapeutics Inc (NASDAQ: PTCT) Right Now?
The 36-month beta value for PTCT is at 0.58. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 as “hold,” and 1 as “sell.”
The public float for PTCT is 76.82M, and currently, shorts hold a 5.60% of that float. The average trading volume for PTCT on April 01, 2025 was 775.01K shares.
PTCT) stock’s latest price update
PTC Therapeutics Inc (NASDAQ: PTCT)’s stock price has decreased by -3.91 compared to its previous closing price of 50.96. However, the company has seen a -12.98% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-28 that WARREN, N.J., March 28, 2025 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units (“RSUs”), each representing the right to receive one share of its common stock upon vesting, to 35 new employees.
Analysts’ Opinion of PTCT
Many brokerage firms have already submitted their reports for PTCT stocks, with BofA Securities repeating the rating for PTCT by listing it as a “Neutral.” The predicted price for PTCT in the upcoming period, according to BofA Securities is $55 based on the research report published on March 11, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $55. The rating they have provided for PTCT stocks is “Sector Perform” according to the report published on March 07th, 2025.
Morgan Stanley gave a rating of “Overweight” to PTCT, setting the target price at $67 in the report published on December 13th of the previous year.
PTCT Trading at -4.22% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.12% of loss for the given period.
Volatility was left at 4.69%, however, over the last 30 days, the volatility rate increased by 5.58%, as shares sank -6.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.79% upper at present.
During the last 5 trading sessions, PTCT fell by -13.68%, which changed the moving average for the period of 200-days by +28.94% in comparison to the 20-day moving average, which settled at $54.20. In addition, PTC Therapeutics Inc saw 8.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Pauwels Eric, who sale 6,762 shares at the price of $56.80 back on Mar 17 ’25. After this action, Pauwels Eric now owns 72,640 shares of PTC Therapeutics Inc, valued at $384,067 using the latest closing price.
Pauwels Eric, the CHIEF BUSINESS OFFICER of PTC Therapeutics Inc, sale 4,458 shares at $55.19 during a trade that took place back on Mar 14 ’25, which means that Pauwels Eric is holding 79,402 shares at $246,037 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.86 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.45. The total capital return value is set at -0.26.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated 1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at -2.25. The interest coverage ratio of the stock is -1.77.
Currently, EBITDA for the company is -120.46 million with net debt to EBITDA at -13.52. When we switch over and look at the enterprise to sales, we see a ratio of 6.9. The receivables turnover for the company is 5.09for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In conclusion, PTC Therapeutics Inc (PTCT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
